Mar
28
Tue
BioHaven Presents: Biohaven Pharmaceuticals – Targeting Orphan Neurologic Indications and Other Neurological Pathways @ Anylan Center at Yale
Mar 28 @ 4:00 pm – 6:00 pm

Host:

Susan Froshauer, Ph.D., President & CEO of CURE, President of CURE Innovations, LLC

Susan is an experienced scientist, mentor, entrepreneur and angel investor with skill at connecting academic expertise and technology with the commercial sector. Susan is involved with the Yale Entrepreneurial Institute, the CTNEXT funded group, SECT Tech, the Creative Arts Workshop and the Angel Investor Forum. Prior to joining CURE, Dr. Froshauer was Director of the Technology Exchange Portal at the University of Connecticut’s Office of Economic Development. In this role Susan assisted Connecticut-based entrepreneurs and organizations with initiatives that train students, create jobs and contribute to economic development. She connected ideas with business expertise, business plans with investors and industry with scholars. Her passion and commitment is helping bioscience entrepreneurs build successful companies.

Speaker:

Vlad Coric, M.D.
Chief Executive Officer and Director, Biohaven Pharmaceuticals, Inc.

Dr. Coric has served as the chief executive officer and director of Biohaven since October 2015. Biohaven is a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders.  Dr. Coric has helped Biohaven raise over $100M since its inception, and investors include leading biotech funds such as Venrock, RA Capital Management, Vivo Capital, Aisling Capital, Rock Springs Capital, John W. Childs, Knoll Capital Management, Osage University Partners, Aperture Venture Partners, Connecticut Innovations, Greg Bailey and Litmore Capital.

Dr. Coric has more than 15 years of drug discovery and clinical development experience at Yale School of Medicine and Bristol-Myers Squibb. Within the pharmaceutical industry, Dr. Coric has expertise working across therapeutic areas including neuroscience, virology, oncology and immuno-oncology. Most recently, Dr. Coric was the immuno-oncology indication lead for neuro-oncology and glioblastoma. He has been involved in multiple drug development programs including marketed drugs such as ABILIFY® (aripiprazole; partial dopamine agonist), OPDIVO® (nivolumab; anti-PD1), YERVOY® (Ipilimumab; anti-CTLA-4), DAKLINZA® (daclatasvir; NS5A inhibitor) and SUNVEPRA® (asunaprevir; NS3 inhibitor). He has conducted numerous clinical trials in various illnesses including obsessive compulsive disorder, generalized anxiety disorder, major depression, schizophrenia, schizoaffective disorder, Alzheimer’s disease, hepatocellular carcinoma, and glioblastoma. Dr. Coric was the first to report the therapeutic effects of the glutamate-modulating agent riluzole in neuropsychiatric disorders (Coric et al., 2003; 2005; Sanacora et al., 2004) and led the first clinical trial employing cerebrospinal fluid biomarkers to identity and enrich for patients with Prodromal Alzheimer’s Disease while at Bristol-Myers Squibb (Coric et al 2015). Additionally, Dr. Coric spearheaded the design of and led the first global registrational trial using checkpoint inhibitors in glioblastoma. Dr. Coric is an Associate Clinical Professor of Psychiatry at the Yale School of Medicine and has over 50 peer-reviewed publications. He previously served as Chief of the Yale Clinical Neuroscience Research Unit, and Director of the Yale Obsessive-Compulsive Disorder Research Clinic. He has served as President of the Connecticut Psychiatric Society (an 800 member district branch of the American Psychiatric Association). Dr. Coric completed residency training at the Yale Psychiatry Residency Training Program, where he also served as the Program-Wide Chief Resident for the Yale Department of Psychiatry, and Chief Resident on the PTSD firm at the West-Haven Connecticut Veterans Administration Hospital. Dr. Coric earned his medical degree at Wake Forest University School of Medicine in North Carolina.

Sponsors:

 

 

Apr
25
Tue
BioHaven Presents: Dr. John LaMattina – The Biopharmaceutical Industry’s Challenges in Drug Pricing @ The Anlyan Center at Yale
Apr 25 @ 4:00 pm – 6:00 pm

CURE is very pleased that Dr. LaMattina has agreed to return to our Biohaven series to discuss drug pricing transparency.   This discussion is suitable for the general public, legislators, students, faculty, and healthcare stakeholders.

Host:

Susan Froshauer, Ph.D., President & CEO of CURE, President of CURE Innovations, LLC

Susan is an experienced scientist, mentor, entrepreneur and angel investor with skill at connecting academic expertise and technology with the commercial sector. Susan is involved with the Yale Entrepreneurial Institute, the CTNEXT funded group, SECT Tech, the Creative Arts Workshop and the Angel Investor Forum. Prior to joining CURE, Dr. Froshauer was Director of the Technology Exchange Portal at the University of Connecticut’s Office of Economic Development. In this role Susan assisted Connecticut-based entrepreneurs and organizations with initiatives that train students, create jobs and contribute to economic development. She connected ideas with business expertise, business plans with investors and industry with scholars. Her passion and commitment is helping bioscience entrepreneurs build successful companies.

 

Speaker:

Dr. John LaMattina is the former Senior Vice President of Pfizer Inc. and former President of Pfizer Global Research and Development. In that role, Dr. LaMattina oversaw the drug discovery and development efforts of over 12,000 colleagues in the United States, Europe and Asia. During his tenure as head of global R&D, Pfizer produced new treatments for cancer, smoking cessation, rheumatoid arthritis and AIDS.

Dr. LaMattina is the author of numerous scientific publications and holds a number of U.S. patents. In addition, he is the author of “Drug Truths: Dispelling the Myths About Phama R&D” and “Devalued and Distrusted – Can the Pharmaceutical Industry Restore Its Broken Image?” He is also a contributor to Forbes.com.

He is currently a Senior Partner at PureTech Health and serves on the Board of Directors of Ligand Pharmaceuticals, Zafgen, Gelesis and Vedanta Biosciences.

 

Thank You to Our Sponsors:

 

Jun
13
Tue
CURE Annual Meeting & The Annual Bioscience & Technology Community Picnic @ CURE Innovation Commons
Jun 13 @ 4:00 pm – 7:00 pm

Join us for The CURE Annual Meeting on June 13th from 4:00PM to 5:00PM and The Annual Bioscience & Technology Community Picnic at The Commons on June 13th from 5:00PM to 7:00PM. 

More details to follow.